Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.

Authors:
Zhu H; Gao H; Ji Y; Zhou Q; Du Z and 4 more

Journal:
J Hematol Oncol

Publication Year: 2022

DOI:
10.1186/s13045-022-01314-3

PMCID:
PMC9277894

PMID:
35831864

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Hematol Oncol

Abbreviation: J Hematol Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion.
Zhao Z; Qin J; Qian Y and 11 more (2024) - Transparency Score: 3/6
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future impl…
Zhao B; Wu B; Feng N and 4 more (2023) - Transparency Score: 3/6
Amino acid metabolism in immune cells: essential regulators of the effector functions, and promisin…
Yang L; Chu Z; Liu M and 7 more (2023) - Transparency Score: 3/6
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and …
Short NJ; Muftuoglu M; Ong F and 24 more (2023) - Transparency Score: 4/6
A pH-dependent anti-CD47 antibody that selectively targets solid tumors and improves therapeutic ef…
Li Y; Liu J; Chen W and 13 more (2023) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsThe authors declare no conflict of interest. Competing interests The authors declare no conflict of interest."

Evidence found in paper:

"Funding The work is supported by the National Natural Science Foundation of China (No. 8210131157), Wuxi Municipal Health Commission (Nos. Q202101, Q202167, M202167 and ZH202110), Wuxi Taihu Talent Project (Nos. WXTTP2020008 and WXTTP2021), Wuxi Medical Development Discipline Project (No. FZXK2021012), Jiangsu Research Hospital Association for Precision Medication (JY202105)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025